Rapid Molecular Detection of Sepsis Using Blood Tests in the Intensive Care Unit

What this Trial Is About

Rapid and accurate diagnosis of sepsis is essential for effective treatment and improving survival rates. Current blood culture methods take 48 hours to 5 days and are unreliable after starting antimicrobial treatment, often leading to broad spectrum antibiotic use which increases resistance. This research aims to develop and validate a new molecular diagnostic test that detects bacterial DNA directly from blood, offering a faster alternative to traditional culture methods. The study focuses on creating and testing rapid diagnostics that identify bacterial DNA causing sepsis within two years. It will also analyze how bacterial DNA levels change over time in patients. Additionally, a physician evaluation panel will compare the new tests results with current blood culture standards to distinguish true infections from contaminations. Participants will be patients for whom routine blood cultures are ordered to diagnose bloodstream infections. Researchers will collect blood samples and monitor bacterial DNA patterns using the new molecular tests. The study will assess test accuracy and dynamics of infection markers, aiming to improve early pathogen identification and treatment decisions. The total study period for outcomes review is two years.

Rapid Molecular Diagnosis of Sepsis in the Intensive Care Unit